IDRx to Be Acquired by GSK for $1 Billion Upfront, And Additional $150 Million in Milestones
January 14, 2025
January 14, 2025
BOSTON, Massachusetts, Jan. 14 -- Goodwin, a law firm, issued the following news release:
The Public M&A and Life Sciences teams advised IDRx, Inc. on its agreement to be acquired by GSK plc (LSE/NYSE: GSK) for $1 billion upfront, with potential for an additional $150 million success-based regulatory approval milestone payment. The acquisition includes lead molecule, IDRX-42, a highly selective KIT TKI being developed as a first- and second-line therapy for the treatment of GIST . . .
The Public M&A and Life Sciences teams advised IDRx, Inc. on its agreement to be acquired by GSK plc (LSE/NYSE: GSK) for $1 billion upfront, with potential for an additional $150 million success-based regulatory approval milestone payment. The acquisition includes lead molecule, IDRX-42, a highly selective KIT TKI being developed as a first- and second-line therapy for the treatment of GIST . . .